1. Scrip
  2. >>Conferences
  3. >>ASCO

Adaptimmune ‘Neck And Neck’ For First Solid Tumor T-Cell Therapy Nod For Afami-Cel

Company Looks Beyond Small Sarcoma Market For Afamitresgene Autoleucel

 
• By Alaric DeArment

The company’s CEO and chief medical officer talked about some challenges as well as opportunities and what they have learned from the experience of other cell therapies.

T Cell lymphocyte with receptors for cancer cell immunotherapy research 3D render
Adaptimmune is reporting initial data from the SPEARHEAD-1 study of afami-cel at ASCO in June • Source: Shutterstock

With the potential to become the first to win US Food and Drug Administration approval for a T-cell therapy in a solid tumor indication, Adaptimmune Therapeutics plc is already thinking about how to commercialize the product, the T-cell receptor (TCR) therapy afamitresgene autoleucel. But while the initial focus will be on the tiny market for synovial sarcoma, the firm has its eye on potentially much larger markets.

The Philadelphia- and Oxfordshire, UK-based company said 19 May that it would report initial data from the pivotal Phase II SPEARHEAD-1 trial of the MAGE-A4-directed TCR afami-cel (formerly ADP-A2M4) in an oral

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

 
• By Alaric DeArment

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO 2024 Wrap-Up Podcast

 
• By Alaric DeArment

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.   

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

 
• By Brian Yang and Dexter Jie Yan

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

More from Conferences

Balance And Focus Suggested For Globalizing Chinese Firms Amid Ongoing Uncertainties

 
• By Xu Hu

Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.

Cash-Strapped Chinese Biotechs A Growing Draw For Western Pharma Partnering

 
• By Alaric DeArment

Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

 
• By Jessica Merrill

CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.